Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
- 736 Downloads
Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have yet to be identified. Preclinical studies implicate angiogenesis in the pathophysiology of more aggressive meningiomas, suggesting that anti-angiogenic therapies may be of utility in this setting. We performed a retrospective review of fourteen patients with recurrent meningioma treated at Duke University Medical Center with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, administered either alone or in combination with chemotherapy. Most patients were heavily pre-treated. Progression-free survival at 6 months was 86 % and was comparable regardless of meningioma grade and whether bevacizumab was administered as monotherapy or in combination with chemotherapy. Most toxicities were mild however single patients developed CNS hemorrhage (grade 1) and intestinal perforation (grade 4), respectively. Bevacizumab can be administered safely to patients with meningioma and appears to be associated with encouraging anti-tumor effect when administered as either a single agent or in combination with chemotherapy. Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted.
KeywordsMeningioma Angiogenesis Vascular endothelial growth factor Bevacizumab
This work was supported by NIH Grants 5P50-NS-20023 and 5 R37 CA11898; NIH Grant MO1 RR 30, GCRC Program, NCRR; and NCI SPORE 1 P20 CA096890; and a grant from Genentech Pharmaceuticals.
The authors thank Wendy Gentry for her excellent secretarial support in the development of this manuscript.
- 1.CBTRUS (2010) CBTRUS: 2010 statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006Google Scholar
- 12.Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-oncology 11:853–860. doi: 10.1215/15228517-2009-010 PubMedCrossRefGoogle Scholar
- 13.Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211–217. doi: 10.1007/s11060-009-9948-7 PubMedCrossRefGoogle Scholar
- 18.Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131–1138Google Scholar
- 29.Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745PubMedCrossRefGoogle Scholar
- 30.Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedCrossRefGoogle Scholar
- 32.DeBoer R, Grimm SA, Chandler J, Gallot L, Kennedy S, Burns K, Rice L, Cabreza C, Muro K, Raizer JJ (2008) A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas. J Clin Oncol [2008 ASCO annual meeting proceedings (post-meeting edition)] 26:2060Google Scholar
- 33.Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE II, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2011) Phase II study of Gleevec((R)) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J. J Neurooncol. doi: 10.1007/s11060-011-0687-1 Google Scholar
- 36.Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157–165. doi: 10.1007/s11060-004-2337-3 PubMedCrossRefGoogle Scholar
- 42.Grunberg SM, Rankin C, Townsend J et al (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unreasectable meningioma. Proc Am Soc Clin Oncol 20:222Google Scholar